Dose-response effect of dietary nitrate on muscle contractility and blood pressure in older subjects

Edgar J. Gallardo¹, Derrick A. Gray¹, Richard L. Hoffman¹,
¹Brandon A. Yates, ²Ranjani N. Moorthi, and Andrew R. Coggan¹

¹Department of Kinesiology, School of Health and Human Science, and ²Department of Internal Medicine, School of Medicine, Indiana University Purdue University Indianapolis

Indianapolis, IN 46112

Address correspondence to: Andrew R. Coggan, PhD
Department of Kinesiology
Indiana University Purdue University Indianapolis
IF 101C, 250 University Boulevard
Indianapolis, IN 46112
Phone: (317) 274-0656
Fax: (317) 274-2041
e-mail: acoggan@iupui.edu

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.
Abstract

Purpose: We have recently demonstrated that dietary nitrate, a source of nitric oxide via the enterosalivary pathway, can improve muscle contractile function in healthy older men and women. Nitrate ingestion has also been shown to reduce blood pressure in some, but not all, studies of older individuals. However, the optimal dose for eliciting these beneficial effects is unknown. Methods: A randomized, double-blind, placebo-controlled crossover study was performed to determine the effects of ingesting 3.3 mL/kg of concentrated beetroot juice (BRJ) containing 0, 200, or 400 µmol/kg of nitrate in nine healthy older subjects (one man, eight women; mean age 70±1 y). Maximal knee extensor power (Pmax) and speed (Vmax) were measured 2 h after BRJ ingestion using isokinetic dynamometry. Blood pressure was monitored periodically throughout each study. Results: Pmax (in W/kg) was higher (P<0.05) after the low dose (3.9±0.4) compared to the placebo (3.7±0.4) or high dose (3.7±0.4). Vmax (in rad/s) also tended higher (P=0.08) in the low (11.9±0.7) compared to the placebo (10.8±0.8) or high dose (11.2±0.8) trials. Eight out of nine subjects achieved a higher Pmax and Vmax after the lower vs. the higher dose. These dose-related changes in muscle contractility paralleled changes in nitric oxide (NO) bioavailability, as reflected by changes in breath NO and plasma 3-nitrotyrosine levels. No significant changes were found in systolic, diastolic, or mean arterial pressure. Conclusions: Varying doses of dietary nitrate have differential effects on muscle function and blood pressure in older individuals. A moderate dose of nitrate increases muscle speed and power, but these improvements are lost at a higher dose. Blood pressure, on the other hand, is not reduced even with a higher dose.

Key words: Nitric oxide, nitrite, isokinetic dynamometry, 3-nitrotyrosine
Roughly ⅓ of individuals over age 65 y suffer from some form of ambulatory or self-care disability (1). In the United States alone, this amounts to some 15 million individuals at present, a number is likely to at least double over the next three decades (1). Similar trends are evident world-wide (1). The primary cause of disability in older persons is a decline in muscle contractile function, with serious difficulty walking or climbing stairs being the most prevalent problem at all ages (1). These functional limitations are highly predictive of dependence, institutionalization, and mortality in the elderly (2,3). Thus, it is clear that age-related changes in muscle function can have an enormous impact not only on a given individual’s quality and length of life but also on the societal costs of caring for an aging population.

Numerous factors contribute to the decline in muscle contractile function with aging. These include a reduction in overall muscle mass, as a result of a decrease in both muscle fiber number and size, as well as alterations in the neural control of muscle (4,5). These contribute to a decrease in strength, i.e., a reduction in the maximal force-generating capacity of muscle. However, the maximal speed of muscle shortening also decreases with aging (6-9), leading to an even more dramatic age-related decline in maximal muscle power, i.e., the product of force and speed (7,8). Moreover, decreases in muscle power with aging are a better predictor of movement disabilities than decreases in strength (9,10). Improving muscle speed and power should therefore logically be the primary focus of any intervention intended to combat muscle dysfunction in the elderly.

We have previously reported that dietary nitrate (NO₃⁻), a source of nitric oxide (NO) via the reduction of NO₃⁻ to nitrite (NO₂⁻) and hence to NO via the action of bacterial NO₃⁻ reductases in the mouth and/or mammalian NO₃⁻ reductases (e.g., xanthine oxidase (XOR)) in the tissues (10), can significantly enhance muscle speed and power in various subject
populations, i.e., healthy young and middle-aged individuals (11,12), athletes (13), patients with heart failure (14). Although the exact mechanisms responsible for this effect are still uncertain, they appear to involve NO-mediated changes in muscle calcium (Ca\(^{2+}\)) release and/or sensitivity (15). More recently, we have demonstrated that acute NO\(^{-}\) ingestion also significantly improves muscle speed and power in healthy elderly subjects (16). These changes were large enough to theoretically offset the reductions resulting from several decades of aging. It is therefore clear that dietary NO\(^{-}\) supplementation holds enormous potential as a means of mitigating muscle dysfunction, and hence disability, in older individuals. The optimal dose of NO\(^{-}\) for eliciting improvements in muscle contractility in elderly persons, however, has not been determined.

In addition to improving muscle function, dietary NO\(^{-}\) supplementation has also been found to reduce blood pressure in a number of subject groups (17). However, a recent meta-analysis concluded that dietary NO\(^{-}\) does not reduce blood pressure in subjects \(\geq 65\) y of age (18). It was hypothesized that this may be due to variations in the oral microbiota and/or other factors (e.g., gastric acid production) that could influence the extent of reduction of NO\(^{-}\) to NO\(^{2-}\) (18). Alternatively, an age-related decline in the expression of the putative NO\(^{-}\) transporter sialin could limit the ability of the salivary glands of older individuals to concentrate and re-secrete NO\(^{-}\) into the oral cavity (19). In either case, larger doses of NO\(^{-}\) may be required to elicit significant increases in plasma NO\(^{2-}\) levels and NO bioavailability, and hence a decrease in blood pressure, in older persons. As with muscle function, however, the effect of NO\(^{-}\) dose on changes in blood pressure in older individuals has not been tested.

The purpose of the present study was to determine the effects of varying doses of dietary NO\(^{-}\) on changes in muscle speed and power and blood pressure in healthy older men and women. Based on previous research (20), we hypothesized that a moderate dose of NO\(^{-}\) would
increase muscle speed and power in such individuals, which would not be further enhanced at a higher dose of NO$_3^\cdot$. Blood pressure, on the hand, would only be significantly reduced at a higher dose of NO$_3^\cdot$.

**Methods**

*Subjects:* Nine healthy, community-dwelling older subjects (one man, eight women) with mean (±SE) age, height, weight, and body mass index of 70±1 y, 1.68±0.03 m, 68.7±4.2 kg, and 24.3±1.3 kg/m$^2$ participated in this study. Potential subjects were assessed during an initial visit to the Clinical Research Center that included a health history and physical examination, resting electrocardiogram, phlebotomy for determination of screening/phenotyping laboratories (CBC, CMP, fasting insulin and lipids), and practicing the entire isokinetic dynamometry testing protocol (see below). Individuals were excluded if they met any of the following criteria: not between the ages of 65-79 y, unable to provide informed consent, were pregnant or lactating, had a history of major metabolic (Type I or II diabetes, thyroid disorders), neuromuscular (e.g., cervical spondylotic radiculomyelopathy, lumbar spondylosis, amyotrophic lateral sclerosis, Guillain-Barré syndrome, acquired demyelinating polyneuropathies), cardiovascular (e.g., moderate or severe valvular disease, myocardial infarction/ischemia, myocardial/pericardial disease, stage II or greater hypertension, heart failure), renal (eGFR <60 mL/min/1.73 m$^2$ or 61-90 mL/min/1.73m$^2$ and albumin:creatinine ratio >30), or liver (i.e., SGOT/SGPT > 2x normal) disease, were anemic (hematocrit <30%), or had any other contraindications to vigorous exercise. They were also excluded from the study if they currently smoked or were taking proton pump inhibitors, antacids, xanthine oxidase inhibitors, or were on hormone replacement therapy, as these can interfere with the reduction of NO$_3^\cdot$ to NO$_2^\cdot$ and then NO (21-23). Individuals on phosphodiesterase inhibitors were also excluded, as these can potentiate the effects of NO (24).
The study was approved by the Human Subjects Office at Indiana University, and written, informed consent was obtained from each subject.

**Experimental design and protocol:** Following completion of the initial screening visit, eligible volunteers were studied using a randomized, double-blind, placebo-controlled crossover design. They were asked to avoid sympathetic stimulation (caffeine, alcohol) and fast for 12 h prior to testing. Upon arrival at the University Hospital Clinical Research Center (CRC), blood pressure, heart rate, and the amount of NO in the breath were measured. An intravenous catheter was then placed, and a baseline blood sample was obtained for subsequent determination of plasma $\text{NO}_3^-$ and $\text{NO}_2^-$ concentrations as described below. The subject then ingested 3.3 mL/kg of a commercial concentrated beetroot juice (BRJ) supplementation (Beet It Sport®, James White Drinks, Ipswich, UK) either: 1) essentially devoid of $\text{NO}_3^-$ (placebo); 2) containing (based on direct measurement) 121 µmol/mL $\text{NO}_3^-$ (thus total dose = 400 µmol/kg); or 3) an equal mixture of the placebo and $\text{NO}_3^-$ containing BRJ products (total dose = 200 µmol/kg). Hemodynamic data and breath/blood samples were collected again after 1 and 2 h of quiet rest, after which muscle contractile function was determined as described below. After a 10 min recovery period, heart rate and blood pressure were again measured and the final breath and blood samples were collected, then the subject was fed lunch and released from the CRC. They subsequently returned to the hospital and repeated the above procedures two more times receiving the other doses, with a 1-2 wk washout period between visits.

**Measurement of muscle contractile function:** Maximal knee extensor power (Pmax, in W/kg) and velocity (Vmax, in rad/s) were measured using an isokinetic dynamometer (Biodex System 4 Pro®, Biodex Medical Systems, Shirley, NY) as previously described in detail (11). Briefly, the femoral condyle of the subject’s dominant leg was aligned with the axis of rotation of the
dynamometer and their torso, waist, thigh, and lower leg tightly restrained with straps to prevent extraneous movement. The subject then performed maximal knee extensions at angular velocities spanning the ascending limb of the power-velocity relationship, i.e., at 0, 1.57, 3.14, 4.71, and 6.28 rad/s (0, 90, 180, 270, and 360 º/sec). Three maximal repetitions were executed at each velocity, with 2 min of rest allowed between each set of contractions. Subjects were instructed to attempt to move as quickly and as forcefully as possible during each repetition, and strong verbal encouragement was provided throughout the testing. To eliminate artifacts, the isokinetic dynamometer data were windowed, filtered, and smoothed as previously described (11), after which peak power at each velocity was calculated by multiplying the peak torque by velocity. Pmax and Vmax were then determined by fitting an inverted parabola to the peak power-velocity relationship (11).

*Measurement of breath NO and plasma NO$^3_-$, NO$^2_-$, and 3-NT:* Breath NO was measured using a portable electrochemical analyzer (NIOX VERO®, Circassia Pharmaceuticals, Mooresville, NC). Plasma NO$^3_-$ and NO$^2_-$ were measured using a dedicated high performance liquid chromatography system (ENO-30, Eicom USA, San Diego, CA) as previously described in detail (25). Briefly, 25 µL of thawed plasma was mixed 1:1 with methanol, centrifuged at 4°C for 10 minutes at 10,000 g, and a 10 µL aliquot of the protein-poor supernatant injected into the HPLC. Plasma NO$^3_-$ and NO$^2_-$ concentrations were calculated based on standard curves generated using NIST-traceable standard solutions. Plasma 3-NT levels were determined using a commercial ELISA kit (OxiSelect™, Cell Biolabs, San Diego, CA).

*Sample size:* The required sample sizes to detect changes in Pmax and Vmax (the primary outcome variables) were estimated based on the respective effect sizes observed in our recent study (16) and assuming $\alpha = 0.05$ and $1-\beta = 0.90$. These calculations indicated that $n=11$ would
be required to detect changes in $P_{\text{max}}$, whereas $n=6$ would be required to detect changes in $V_{\text{max}}$. However, we were only able to study $n=9$ subjects before all non-essential research at our institution was halted due to the COVID-19 pandemic.

Statistical analyses: Statistical analyses were performed using GraphPad Prism version 8.4.1 (GraphPad Software, La Jolla, CA). Normality of data distribution was tested using the D’Agostino-Pearson omnibus test. Peak torque/power data and hemodynamic, breath NO, plasma NO$_3^-$, NO$_2^-$, and 3-NT data were analyzed using two-way (i.e., dose x velocity or dose x time, respectively) repeated measures ANOVA. Changes from baseline (average of 2 h and 10 min post-exercise values) in the latter variables as well as absolute values and changes in $V_{\text{max}}$ and $P_{\text{max}}$ were analyzed using one-way ANOVA. Post-hoc testing was performed using the Holm-Šidák multiple comparison procedure. $P<0.05$ was considered significant.

Results

Markers of NO bioavailability: Plasma NO$_3^-$ and NO$_2^-$ concentrations and breath NO levels did not change following ingestion of the placebo BRJ, whereas ingestion of BRJ containing 200 µmol/kg of NO$_3^-$ resulted in marked elevations in all three (Table 1, Fig. 1A-C). The magnitude of the increases in plasma NO$_3^-$ and NO$_2^-$ over baseline were comparable to those observed in previous studies using similar doses of NO$_3^-$ (e.g., Ref. 20). Ingestion of BRJ containing twice as much NO$_3^-$ (i.e., 400 µmol/kg) resulted in almost exactly double the increase in plasma NO$_3^-$ and NO$_2^-$ concentration (Table 1, Fig. 1A and 1B). In contrast, the level of NO in breath increased less after the higher vs. the lower dose of NO$_3^-$ (Table 1, Fig. 1C), although it was still elevated compared to the placebo trial. Plasma 3-NT concentrations initially decreased then gradually increased during all three trials ($P<0.05$), but these changes tended to be greater during the placebo and low dose trials versus the high dose trial (Table 1, Fig. 1D).
Muscle contractile function: There were no significant effects of NO₃⁻ ingestion on knee extensor peak torque, and hence peak power, at low to moderate angular velocities (i.e., at 0, 1.57, 3.14, or 4.71 rad/s; Table 2). In keeping with our previous results (16), however, ingestion of BRJ containing a moderate amount of NO₃⁻ (i.e., 200 µmol/kg) resulted in a significant increase in peak torque, and hence peak power, at the highest velocity tested (i.e., 6.28 rad/s) (Table 2). This beneficial effect of acute NO₃⁻ supplementation on muscle contractile function was lost when the NO₃⁻ dose was doubled to 400 µmol/kg (Table 2). Correspondingly, Pmax (in W/kg) as calculated from these data was significantly higher (P<0.05) after the low dose (3.9±0.4) compared to the placebo (3.7±0.4) or high dose (3.7±0.4). Vmax (in rad/s) also tended higher (P=0.08) in the low (11.9±0.7) compared to the placebo (10.8±0.8) or high (11.2±0.8) trials. Eight out of nine subjects (including the one man) achieved a higher Pmax and Vmax after ingestion of the lower vs. the higher dose of NO₃⁻ (Figs. 2A-D).

Hemodynamics: Heart rate did not change significantly over time or in response to ingestion of varying amounts of NO₃⁻ (Table 3). Systolic and mean blood pressure, on the other hand, decreased significantly over time (both P<0.01 for main effect), with such changes tending to be greatest in the high dose trial (Table 3). However, neither the treatment main effects nor the treatment x time interaction effects were statistically significant. Diastolic blood pressure did not change significantly with either time or treatment.

Discussion

The purpose of the present study was to determine the effect of varying doses of dietary NO₃⁻ on changes in muscle contractile function and blood pressure in healthy older individuals. We found that a moderate dose of NO₃⁻ (i.e., 200 µmol/kg) resulted in measurable improvements in maximal knee extensor speed and power, but no significant changes in blood pressure. A larger
dose of NO$_3^-$ (i.e., 400 µmol/kg) also did not significantly alter blood pressure, whereas muscle speed and power actually regressed towards, and in some individuals even below, baseline values. This is the first dose-response study of the effects of acute dietary NO$_3^-$ supplementation on muscle contractile function in any population, and the first to specifically examine changes in blood pressure in older subjects.

We have previously demonstrated that dietary NO$_3^-$ supplementation can enhance muscle contractility in a variety of subject populations (11-14). This includes healthy elderly men and women, in whom acute intake of 13.4±0.5 mmol (182±10 µmol/kg) of NO$_3^-$ increased maximal knee extensor speed and power by 11±2 and 4±4%, respectively (16). The results of the present study are similar, in that Vmax and Pmax improved by 8±4 and 7±3%, respectively, after ingestion of BRJ containing 200 µmol/kg of NO$_3^-$.

The somewhat greater increase in Pmax in the present investigation vs. our previous study could be due to the slightly larger dose of NO$_3^-$ provided. Indeed, in our previous study we observed that individuals who received less than ~150 µmol/kg of NO$_3^-$ were less likely to show significant improvements in muscle function (unpublished observations). Alternatively, it could be due to the greater percentage of women in the present study (i.e., 89 vs. 50%), as we have found that women tend to be more likely to benefit from NO$_3^-$ intake (12). Regardless, as previously discussed these improvements in muscle function are substantial relative to their normal rate of decline with aging, and in fact are roughly comparable to those resulting from several months of traditional resistance exercise training (cf. Ref. 26 for review). As such, dietary NO$_3^-$ supplementation could potentially have a measurable impact on the functional capacity (e.g., walking speed, chair rise time, stair climbing ability) of older persons during daily life, thus minimizing the risk of disability and dependence.
Given the latter, it is imperative to determine the optimal dose (and timing and source, i.e., BRJ vs. a salt) of NO$_3^-$ for enhancing muscle contractile function in older persons. Previous dose-response studies in younger untrained or moderately-trained individuals have found that providing 6-10 mmol (roughly 100-150 µmol/kg) of NO$_3^-$ is generally sufficient to improve economy and/or performance during endurance exercise (20,27-29), with no further improvements at higher doses (i.e., up to 16.8 mmol, or ~225 µmol/kg) (20). As implied above, however, it appears that somewhat higher doses of NO$_3^-$ may be required to increase muscle speed and power, at least in older men and women. Thus, in addition to studying a NO$_3^-$ dose of 200 µmol/kg, we also tested subjects after they had consumed double this dose, i.e., 400 µmol/kg. Based on our previous research and that of Wylie et al. (20), we anticipated that this would result in a quantitatively-similar improvement in muscle contractile function, i.e., that both 200 and 400 µmol/kg would fall on a plateau in the dose-response relationship.

Surprisingly, however, both Vmax and Pmax actually regressed at the higher dose, such that on average they were not significantly different from the placebo trial. This pattern was highly consistent across subjects, with all but one of the subjects performing best with the lower dose, and several of the subjects actually performing worse following the higher dose than during the placebo trial. To our knowledge, this is the first study to demonstrate a possible impairment in exercise performance following ingestion of dietary NO$_3^-$, although both Larsen et al. (30) and Bescós et al. (31) have previously reported that NO$_3^-$ ingestion can reduce VO$_2$max.

The mechanism responsible for the above unanticipated finding is not clear. It does not, however, appear to be due to failure of the higher dose of NO$_3^-$ to further augment plasma NO$_3^-$ and NO$_2^-$ levels, as both rose almost exactly twice as much following the 400 vs. the 200 µmol/kg dose. This is consistent with the essentially complete bioavailability of NO$_3^-$ from...
ingested vegetables (32). Interestingly, however, the availability of NO itself, at least as
measured in the breath, rose less after the higher vs. the lower dose, and thus was significantly
lower in the former vs. the latter experiments. We therefore measured plasma 3-NT
concentrations, as another marker of the rate of NO production but also to determine whether the
higher dose of NO₃⁻ (which averaged 28.7±2.7 mmol) resulted in “peaking over” of muscle
contractile function due to an increase in nitrosative stress. This possibility was suggested by the
recent results of Gholami et al. (33), who reported that ingestion of 24, but not 8 or 16, mmol of
NO₃⁻ resulted in a dramatic increase in plasma peroxynitrite levels in well-trained subjects
following a maximal incremental exercise test. In the present study, however, the pattern of
change in plasma 3-NT instead generally resembled that of breath NO, i.e., tending to increase
slightly after the lower dose but decrease slightly after the higher dose of NO₃⁻.

We interpret the above findings as follows: the lower dose of NO₃⁻ significantly increased
plasma NO₃⁻ concentrations, which led to a rise in plasma (and presumably tissue (34)) NO₂⁻
levels, and hence an increase in NO bioavailability. As a result of the latter, both muscle
contractile function (i.e., Vmax and Pmax) and plasma 3-NT concentrations were elevated (the
latter insignificantly) compared to the placebo trial. Conversely, the higher dose of NO₃⁻ resulted
in even greater increases in plasma NO₃⁻ and NO₂⁻ concentrations, but NO itself actually
increased less than after the lower dose, ostensibly as a result of NO₃⁻ outcompeting NO₂⁻ for
reduction by XOR. Consequently, muscle speed and power did not change significantly, whereas
plasma 3-NT concentrations actually tended to decline. This scenario, which is shown
schematically in Figure 3, is partially based on the observations of Damacena-Angelis et al. (35),
who found that higher concentrations of NO₃⁻ can inhibit XOR-mediated reduction of NO₂⁻ to
NO, and thus partially attenuate the blood pressure lowering effect of NO₂⁻ in rats. Although
speculative, the above hypothesis could explain the present observations. Alternatively, it is possible that the high concentrations of NO$_3^-$ and/or NO$_2^-$ present after ingestion of the higher dose led to a direct inhibitory effect on muscle contractile function, e.g., by enhancing transnitrosylation of myosin (36). This would not, however, account for the lower NO levels observed following ingestion of the higher dose of NO$_3^-$.

In contrast to the improvements in muscle speed and power observed following ingestion of the lower dose of NO$_3^-$, blood pressure was unaltered by either the lower or the higher dose. This finding is consistent with a recent meta-analysis by Siervo et al. (18) but runs counter to the results of other studies of older subjects (37-39). The reason for these divergent results is uncertain. The amount of NO$_3^-$ provided in the present experiments is much higher than used in these previous studies, such that an inadequate dose can seemingly be ruled out. It is possible that the subjects we studied were resistant to the potential blood pressure-lowering effects of dietary NO$_3^-$ due to excessive oxidative stress, since NO$_3^-$ plus ascorbic acid but not NO$_3^-$ alone has been reported to reduce systolic and mean arterial blood pressure in older adults (40). It is also possible, however, that the failure to detect a statistically-significant NO$_3^-$-induced reduction in blood pressure in the present study is simply a type 2 statistical error, due to the well-known variability of blood pressure measurements combined with a relatively small number of subjects. This is so because 1) changes in blood pressure from baseline were numerically greater after NO$_3^-$ ingestion (i.e., -8±3, -11±4, and -16±4, -1±2, -2±2, and -4±2, and -4±2, -5±2, and -8±2 mmHg for systolic, diastolic, and mean arterial pressure in the placebo, 200 µmol/kg, and 400 µmol/kg trials, respectively), and 2) post-hoc analysis of the data demonstrated that, given the observed effect sizes, the achieved powers (i.e., 1-β) with n=9 subjects were only 0.64, 0.67, and 0.83, respectively.
There are both strengths and weaknesses to the present study. A major strength is the use of a highly-reliable method for assessing maximal muscle contractile properties, even in older subjects. For example, as calculated from the ANOVA the intraclass correlation coefficient (ICC) for Pmax was 0.98. This helps explain why we were able to detect statistically-significant changes in muscle contractile function but not in, e.g., systolic blood pressure (ICC=0.70). Another strength is that, unlike in previous dose-response studies (20,27-29), in the present experiments the dose of NO\textsuperscript{3−} was adjusted relative to body mass, thus at least theoretically minimizing inter-subject variability in peak plasma NO\textsuperscript{3−} concentrations due to differences in the volume of distribution. At the same time, we kept the volume of BRJ the same across trials, thus eliminating differences in the amount of other potentially biologically-active compounds (e.g., carotenoids, betalains, bioflavonoids, ascorbic acid) as a source of variability. As discussed above, a weakness of our study is that it was slightly underpowered to detect possible differences in blood pressure due to NO\textsuperscript{3−} ingestion. Another weakness is that by studying only two doses of NO\textsuperscript{3−}, i.e., 200 and 400 µmol/kg, it is not possible to determine whether the optimal dose is somewhat less than 200 µmol/kg or somewhere between 200 and 400 µmol/kg. At a minimum, however, the present data provide a starting point for further experiments.

In summary, in the present study we have examined the dose-response relationship between dietary NO\textsuperscript{3−} supplementation and changes in both muscle contractile function and blood pressure in healthy older subjects. We found that although blood pressure was unchanged, ingestion of a lower, but not a higher, dose of NO\textsuperscript{3−} significantly increased maximal knee extensor power, with these divergent results seemingly reflecting the failure of the higher dose to sufficiently elevate NO bioavailability. Future studies should use the tools and approaches
commonly employed in pharmaceutical development (e.g., pharmacokinetic-pharmacodynamic modeling) to further refine this possible treatment for muscle dysfunction in older persons.
Conflicts of Interest and Source of Funding

This work was supported by grants from the Office of the Vice Provost for Research at Indiana University Purdue University Indianapolis and the National Institute on Aging (R21 AG053606) to A.R. Coggan; the National Heart, Lung, and Blood institute (R34 HL138253) to A.R. Coggan and Linda R. Peterson; the National Institute on Diabetes, Digestive, and Kidney Diseases (K23 DK102824) to R.N. Moorthi, the National Institute on Arthritis and Musculoskeletal and Skin Disease (P30 AR072581) to Sharon Mo; and the National Center for Advancing Translational Sciences (UL1 TR002529) to Anantha Shekhar. For the remaining authors no conflicts of interest are declared. The contents of this article are solely the responsibility of the authors and does not necessarily represent the official view of the National Institutes of Health or the American College of Sports Medicine. The results of the study are presented clearly, honestly, and without fabrication, falsification, or inappropriate data manipulation.


5. da Rosa Orssatto LB, Wiest MJ, Diefenthaler F. Neural and musculotendinous mechanisms underpinning age-related force reductions. *Mech Ageing Dev* 2018;175(10):17-23. [https://doi.org/10.1016/j.mad.2018.06.005](https://doi.org/10.1016/j.mad.2018.06.005)


21. Lundberg JO, Weitzberg E, Lundberg JM, Alving K. Intragastic nitric oxide production in humans: measurements in expelled air. *Gut* 1994;35(11):1543-1546. [https://doi.org/10.1136/gut.35.11.1543](https://doi.org/10.1136/gut.35.11.1543)


27. Flueck JL, Bogdanova A, Mettler S, Perret C. Is beetroot juice more effective than sodium nitrate? The effects of equimolar nitrate dosages of nitrate-rich beetroot juice and sodium


Table 1. Effect of varying doses of dietary NO$_3^-$ on plasma NO$_3^-$, plasma NO$_2^-$, breath NO, and plasma 3-nitrotyrosine in healthy older subjects.

<table>
<thead>
<tr>
<th>Time of measurement</th>
<th>Dose of NO$_3^-$ (µmol/kg)</th>
<th>Pre ingestion</th>
<th>1 h post</th>
<th>2 h post</th>
<th>10 min post</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>0</td>
<td>55±10</td>
<td>57±5</td>
<td>67±6</td>
<td>66±5</td>
</tr>
<tr>
<td>Plasma NO$_3^-$</td>
<td>200</td>
<td>40±5</td>
<td>523±52</td>
<td>624±53</td>
<td>628±47</td>
</tr>
<tr>
<td>(µmol/L)</td>
<td>400</td>
<td>34±5</td>
<td>793±73</td>
<td>1184±89</td>
<td>1296±94</td>
</tr>
<tr>
<td></td>
<td>0</td>
<td>0.31±0.05</td>
<td>0.30±0.02</td>
<td>0.33±0.04</td>
<td>0.35±0.05</td>
</tr>
<tr>
<td>Plasma NO$_2^-$</td>
<td>200</td>
<td>0.31±0.04</td>
<td>0.46±0.07</td>
<td>0.53±0.07</td>
<td>0.82±0.18</td>
</tr>
<tr>
<td>(µmol/L)</td>
<td>400</td>
<td>0.34±0.06</td>
<td>0.48±0.06</td>
<td>0.95±0.18</td>
<td>1.22±0.15</td>
</tr>
<tr>
<td></td>
<td>0</td>
<td>19±3</td>
<td>22±3</td>
<td>25±3</td>
<td>21±3</td>
</tr>
<tr>
<td>Breath NO (ppb)</td>
<td>200</td>
<td>18±3</td>
<td>39±6</td>
<td>43±7</td>
<td>50±10</td>
</tr>
<tr>
<td></td>
<td>400</td>
<td>18±3</td>
<td>31±4</td>
<td>36±4</td>
<td>36±6</td>
</tr>
<tr>
<td></td>
<td>0</td>
<td>177±20</td>
<td>153±18</td>
<td>170±19</td>
<td>217±27</td>
</tr>
<tr>
<td>3-Nitrotyrosine</td>
<td>200</td>
<td>170±22</td>
<td>158±19</td>
<td>176±23</td>
<td>216±27</td>
</tr>
<tr>
<td>(nmol/L)</td>
<td>400</td>
<td>237±25</td>
<td>209±22</td>
<td>198±26</td>
<td>250±34</td>
</tr>
</tbody>
</table>

Values are mean±SE for n=9. Significantly different from 0 µmol/kg dose: *P<0.05, †P<0.01, ‡P<0.001. Significantly different from 200 µmol/kg dose: §P<0.05, ¶P<0.001.
Table 2. Effect of varying doses of dietary NO$_3^-$ on peak knee extensor torque and power as a function of velocity in healthy older subjects.

<table>
<thead>
<tr>
<th>Angular velocity (rad/s)</th>
<th>Dose of NO$_3^-$ (µmol/kg)</th>
<th>0</th>
<th>1.57</th>
<th>3.14</th>
<th>4.71</th>
<th>6.28</th>
</tr>
</thead>
<tbody>
<tr>
<td>Peak torque (Nm/kg)</td>
<td>0</td>
<td>1.79±0.15</td>
<td>1.21±0.10</td>
<td>0.91±0.06</td>
<td>0.75±0.06</td>
<td>0.55±0.06</td>
</tr>
<tr>
<td></td>
<td>200</td>
<td>1.86±0.15</td>
<td>1.24±0.07</td>
<td>0.92±0.06</td>
<td>0.78±0.06</td>
<td>0.61±0.06†</td>
</tr>
<tr>
<td></td>
<td>400</td>
<td>1.78±0.12</td>
<td>1.24±0.07</td>
<td>0.90±0.05</td>
<td>0.74±0.06</td>
<td>0.56±0.06</td>
</tr>
<tr>
<td>Peak power (W/kg)</td>
<td>0</td>
<td>0.00±0.00</td>
<td>1.97±0.15</td>
<td>2.91±0.22</td>
<td>3.59±0.30</td>
<td>3.46±0.45</td>
</tr>
<tr>
<td></td>
<td>200</td>
<td>0.00±0.00</td>
<td>1.95±0.11</td>
<td>2.89±0.20</td>
<td>3.69±0.27</td>
<td>3.83±0.37†</td>
</tr>
<tr>
<td></td>
<td>400</td>
<td>0.00±0.00</td>
<td>1.94±0.11</td>
<td>2.84±0.17</td>
<td>3.48±0.28</td>
<td>3.49±0.39</td>
</tr>
</tbody>
</table>

Values are mean±SE for n=9. Significantly different from 0 or 400 µmol/kg doses: †P<0.01.
Table 3. Effect of varying doses of dietary NO$_3^-$ on heart rate and blood pressure in healthy older subjects.

<table>
<thead>
<tr>
<th>Dose of NO$_3^-$ (µmol/kg)</th>
<th>Time of measurement</th>
<th>Heart rate (beats/min)</th>
<th>Systolic blood pressure (mmHg)</th>
<th>Diastolic blood pressure (mmHg)</th>
<th>Mean arterial pressure (mmHg)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Pre ingestion</td>
<td>1 h post ingestion</td>
<td>2 h post ingestion</td>
<td>10 min post exercise</td>
<td></td>
</tr>
<tr>
<td>0</td>
<td>73±4</td>
<td>72±3</td>
<td>70±3</td>
<td>73±3</td>
<td></td>
</tr>
<tr>
<td>200</td>
<td>71±4</td>
<td>74±3</td>
<td>70±3</td>
<td>73±2</td>
<td></td>
</tr>
<tr>
<td>400</td>
<td>72±3</td>
<td>70±3</td>
<td>71±3</td>
<td>74±3</td>
<td></td>
</tr>
<tr>
<td>0</td>
<td>131±5</td>
<td>122±4</td>
<td>122±3</td>
<td>125±4</td>
<td></td>
</tr>
<tr>
<td>200</td>
<td>130±4</td>
<td>122±6</td>
<td>121±5</td>
<td>119±6</td>
<td></td>
</tr>
<tr>
<td>400</td>
<td>134±4</td>
<td>121±4</td>
<td>118±5</td>
<td>118±6</td>
<td></td>
</tr>
<tr>
<td>0</td>
<td>70±2</td>
<td>68±2</td>
<td>68±3</td>
<td>69±2</td>
<td></td>
</tr>
<tr>
<td>200</td>
<td>69±4</td>
<td>67±3</td>
<td>67±3</td>
<td>68±4</td>
<td></td>
</tr>
<tr>
<td>400</td>
<td>69±3</td>
<td>62±3</td>
<td>64±4</td>
<td>65±3</td>
<td></td>
</tr>
<tr>
<td>0</td>
<td>90±2</td>
<td>86±2</td>
<td>86±2</td>
<td>87±2</td>
<td></td>
</tr>
<tr>
<td>200</td>
<td>90±3</td>
<td>85±3</td>
<td>85±3</td>
<td>85±3</td>
<td></td>
</tr>
<tr>
<td>400</td>
<td>90±3</td>
<td>82±3</td>
<td>82±3</td>
<td>82±3</td>
<td></td>
</tr>
</tbody>
</table>

Values are mean±SE for n=9.
Figure legends

Figure 1. Changes (Δ) in plasma nitrate (NO₃⁻; panel A), nitrite (NO₂⁻; panel B), breath nitric oxide (NO; panel C), and plasma 3-nitrotyrosine (3-NT; panel D) in response to varying doses of dietary NO₃⁻ in healthy older subjects. Values are mean±SE for n=9. Significantly different from 0 µmol/kg dose: *P<0.05, ‡P<0.001. Significantly different from 200 µmol/kg dose: §P<0.05, ¶P<0.001.

Figure 2. Individual absolute and relative changes (Δ) in maximal knee extensor power (Pmax; panels A and B) and velocity (Vmax; panels C and D) in response to varying doses of dietary nitrate (NO₃⁻) in healthy older subjects.

Figure 3. Proposed explanation for the effect of varying doses of dietary nitrate (NO₃⁻) on muscle contractile function in healthy older subjects. A lower dose of NO₃⁻ (i.e., 200 µmol/kg) is hypothesized to result in a significant increase in muscle NO₃⁻ concentration, which is reduced by xanthine oxidoreductase (XOR) to nitrite (NO₂⁻) and then to nitric oxide (NO), leading to significant improvements in maximal knee extensor power (Pmax) and velocity (Vmax) and also to an increase in 3-nitrotyrosine (3-NT) formation. In contrast, a higher dose of NO₃⁻ (i.e., 400 µmol/kg) actually results in less of an increase in NO production, due to substrate competition between NO₃⁻ and NO₂⁻ for XOR. As a result, Pmax, Vmax, and 3-NT are unchanged, or possibly even diminished.